Our aim was to investigate the association between serum heat-shock protein (Hsp) 70 concentration and hypertensive disorders of pregnancy. One hundred and forty-two pregnant women with hypertensive disorders (93 with preeclampsia, 29 with transient hypertension of pregnancy and 20 with superimposed preeclampsia) and 127 normotensive, healthy pregnant women were included in the study. Serum Hsp70 concentration was measured using enzyme-linked immunosorbent assay. The serum Hsp70 concentration was significantly higher in patients with transient hypertension of pregnancy, in preeclamptic patients and in patients with superimposed preeclampsia than in the control group (median (25-75 percentile): 0.66 (0.52-0.84), 0.55 (0.42-0.80), 0.61 (0.42-0.91) ng/ml vs 0.31 (0.27-0.39) ng/ml, respectively; Po0.001). Multivariate logistic regression analysis showed independent association of elevated serum Hsp70 level with transient hypertension of pregnancy, preeclampsia and superimposed preeclampsia.
Introduction
Heat-shock proteins (Hsps) are highly conserved molecules, which are present from eubacteria to humans, and have molecular chaperone and cytoprotective functions. Their expression can be induced by several physiological, pathological and environmental conditions. 1 Hsps are usually considered to be intracellular proteins. However, they can be expressed on the cell surface, 2, 3 and they can also be released into the extracellular milieu from viable cells. [4] [5] [6] [7] Hsp60 and Hsp70 have been found in the serum and plasma of healthy individuals. [8] [9] [10] [11] Several human and animal studies have been carried out to determine the role of Hsp70 in the pathogenesis of hypertension and associated diseases. The expression of Hsp70 is markedly increased during acute hypertension in rat aorta. Hsp70 expression induced by heat stress was found to be higher in peripheral blood lymphocytes from hypertensive humans compared to those from normotensive humans. 13 In addition, circulating Hsp70 levels are elevated in patients with peripheral and renal vascular disease.
14 However, no association was found between serum Hsp70 levels and borderline or established hypertension. 15, 16 In contrast, the progression of carotid atherosclerosis in subjects with established hypertension is not as prevalent in subjects having high serum Hsp70 levels. 17 In another study, Hsp70 levels were found to be lower in patients with coronary artery disease, and the severity of the disease was also inversely associated with circulating Hsp70 levels. 18 Nevertheless, little is known about circulating Hsp70 in pregnancy and its association with hypertensive disorders of pregnancy, which are major causes of maternal and perinatal morbidity and mortality, even in developed countries. The aetiology of preeclampsia as well as transient hypertension of pregnancy is unknown. It has been suggested that placental ischaemia, oxidative stress and maternal systemic inflammatory response are involved in the pathogenesis of preeclampsia. [19] [20] [21] These conditions as well as haemodynamic stress (acute hypertension) are also able to induce Hsp70 expression. 1, 12, 22 Three studies exist regarding circulating Hsp70 concentrations in preeclampsia, which are contradictory and partly limited by the low number of patients involved and by low power, as well as by the heterogeneous control group. [23] [24] [25] In addition, pregnant women with transient hypertension and superimposed preeclampsia were not included in these studies. Therefore, the aim of our study was to determine in a larger casecontrol study whether serum Hsp70 concentration is associated with hypertensive disorders of pregnancy.
Patients and methods

Patients
All patients were enrolled in the Department of Obstetrics and Gynecology in Kú tvö lgyi Clinical Center and in the 1st Department of Obstetrics and Gynecology, at the Semmelweis University, Budapest, Hungary. We included 142 pregnant women with hypertensive disorders (93 with preeclampsia, 29 with transient hypertension of pregnancy and 20 with superimposed preeclampsia) and 127 normotensive (blood pressure o140 mm Hg systolic and o90 mm Hg diastolic), healthy pregnant women with uncomplicated pregnancies in the study. All women were of Caucasian origin. Exclusion criteria were multifoetal gestation, diabetes mellitus, autoimmune disease, angiopathy, renal disease, maternal or foetal infection and foetal congenital anomaly. The women were fasting, none were in active labour, and none had rupture of membranes. Control patients were consecutively selected from a group of normotensive, healthy pregnant women in outpatient clinics, who were undergoing routine blood tests, and were excluded if they later developed hypertensive disorder.
Hypertensive disorders complicating pregnancy were diagnosed according to the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy guidelines. 26 In each case, the definitive diagnosis was made retrospectively, post-partum. Transient hypertension of pregnancy was defined by increased blood pressure (X140 mm Hg systolic or X90 mm Hg diastolic on X2 occasions at least 6 h apart) without proteinuria that developed in a woman after 20 weeks of gestation, and blood pressure returned to normal by 12 weeks post-partum. Preeclampsia was determined by increased blood pressure that occurred after 20 weeks of gestation in a woman with normal blood pressure previously, accompanied by proteinuria (X0.3 g/24 h). The diagnosis of superimposed preeclampsia was based on the development of signs of preeclampsia in a pregnant woman with chronic hypertension. (Chronic hypertension was defined as hypertension that was present and observable before pregnancy or was diagnosed before the 20th week of gestation, as well as hypertension that was diagnosed for the first time during pregnancy and did not resolve post-partum.) Severe preeclampsia was diagnosed if any of the following criteria was present: blood pressure X160 mm Hg systolic or X110 mm Hg diastolic, proteinuriaX5 g/24 h or foetal growth restriction. 27 Two patients with eclampsia were included in the severe preeclamptic group. Pregnant women with HELLP syndrome (haemolysis, elevated liver enzymes, low platelets) were not enrolled in this study. Early onset of preeclampsia was defined as onset of the disease before 34 weeks of gestation. Foetal growth restriction was diagnosed if the foetal birth weight was below 10th percentile.
The study protocol was approved by the Regional, Institutional Committee of Medical Ethics at the Semmelweis University, and informed written consent was obtained from each patient.
Biological samples
Maternal blood samples were obtained from an antecubital vein and centrifuged at room temperature at 3000 r.p.m. for 10 min. The serum was stored at À801C until the analysis was performed.
Serum Hsp70 analysis
Soluble Hsp70 level was measured by using R&D Systems (Minneapolis, MN, USA, Catalogue No. DYC1663E) enzyme-linked immunosorbent assay kit. Ninety-six-well microtitre plates were coated with mouse anti-human Hsp70 capture antibody (100 ml; 2 mg/ml) in carbonate buffer (pH 9.5) overnight at 41C. Plates were washed with phosphatebuffered saline (PBS) containing 0.1% Tween 20 three times and nonspecific binding sites blocked by incubation with 200 ml of PBS containing 0.5% gelatinec and Tween 20 for 1 h at room temperature. After washing, 100 ml of the reference preparation (recombinant human Hsp70, 0-10 mg/ml) or samples (1:1) were added and the plates were incubated for 2 h at room temperature. Plates were subsequently washed and Hsp70 binding was determined using biotinylated rabbit anti-human antibody (100 ml; 0.5 mg/ml) in PBS gelatine. After 1.5 h at room temperature, plates were washed and incubated with streptavidin-horseradish-peroxidase (1:200) in PBS gelatine for 20 min at room temperature. Plates were washed and 100 ml of o-phenylenediamine (Sigma, St Louis, MO, USA) in citrate buffer was added. The optical density was measured at l ¼ 490 nm (reference at l ¼ 620 nm). The detection range of the assay was 0.05-10 ng/ml, the intra/ inter-assay variability o10/o16%, respectively.
Statistics
The normality of continuous variables was tested using Shapiro-Wilk's W-test. As the continuous variables were not normally distributed, non-parametric statistical methods were used. To compare continuous non-parametric variables between two groups, the Mann-Whitney U-test was used, whereas to compare them between multiple groups, the Kruskal-Wallis analysis of variance (ANOVA) by ranks test was performed. Multiple comparisons of mean ranks for all groups were carried out as post hoc tests. We used Fisher exact and Pearson w 2 tests to compare categorical variables between groups. Multivariate logistic regression was carried out with adjustment for age, body mass index (BMI) at blood draw, smoking status, primiparity and gestational age at blood draw. Statistical analyses were performed using the following software: STATISTICA (version 6.1; StatSoft Inc., Tulsa, OK, USA) and Statistical Package for the Social Sciences (version 13.0 for Windows; SPSS Inc., Chicago, IL, USA). For all statistical analyses, Po0.05 was considered statistically significant.
In this paper, data are presented as median (25-75 percentile) for continuous variables and number (per cent) for categorical variables.
Results
Patient characteristics
The characteristics of the study patients are shown in Table 1 . There were no statistically significant differences in median maternal age and the percentage of smokers and primiparas between the hypertensive groups and the control group. The groups of pregnant women with hypertensive disorders had significantly higher median BMI at blood draw and significantly higher systolic and diastolic blood pressure than the control group. The median gestational age at delivery and, partly therefore, the median foetal birth weight were significantly lower in the preeclamptic and superimposed preeclamptic groups compared with the control group. In addition, the frequency of foetal growth restriction was significantly higher in patients with transient hypertension of pregnancy, preeclampsia and superimposed preeclampsia than in the control group.
Soluble Hsp70 levels are elevated in transient hypertension of pregnancy, preeclampsia and superimposed preeclampsia The results of the Hsp70 assays are displayed in Table 1 . None of the study patients had serum Hsp70 concentration below the detection limit. The Kruskal-Wallis ANOVA by ranks test revealed significant difference in serum Hsp70 concentration between the groups (Po0.001). According to the post hoc tests, the serum Hsp70 concentration was significantly higher in patients with transient hypertension of pregnancy, in preeclamptic patients and in patients with superimposed preeclampsia than in The preeclamptic and control groups were divided into gestational age subgroups (gestational age at blood draw p32 (group A), 33-35 (group B), 36-37 (group C) and X38 (group D) weeks), as gestational age at blood draw was significantly different between the preeclamptic and control groups. Serum Hsp70 concentrations were also compared between preeclamptic patients and the control group in these gestational age categories, separately. The serum Hsp70 concentrations in the preeclamptic vs control group, with P-values, were as follows: 0.49 (0. 38 To rule out any bias of potential confounding variables, multivariate logistic regression analyses were performed with adjustment for age, BMI at blood draw, smoking status, primiparity and gestational age at blood draw. Using the receiver operating characteristic curve, we determined a cutoff value of serum Hsp70 concentration (with 80.5% specificity and 79.6% sensitivity) regarding hypertensive disorders of pregnancy. High level of serum Hsp70 concentration (serum Hsp70 concentration X0.41 ng/ml) was significantly associated with preeclampsia, transient hypertension of pregnancy and superimposed preeclampsia. The odds ratios of high vs low level of Hsp70 concentration for different classes of hypertensive disorders, with 95% confidence intervals, are shown in Table 2 . There was no significant difference in the risks (in odds ratios) among preeclampsia, transient hypertension and superimposed preeclampsia.
In the group involving preeclamptic and superimposed preeclamptic patients (n ¼ 113), there was no statistically significant difference in serum Hsp70 concentration between patients with mild and severe preeclampsia (0.58 (0.42-0.81) vs 0.54 (0.42-0.74) ng/ml), between patients with late and early onset of the disease (0.59 (0.45-0.84) vs 0.52 (0.36-0.64) ng/ml) as well as between patients without foetal growth restriction and with foetal growth restriction (0.57 (0.41-0.84) vs 0.52 (0.43-0.68) ng/ ml). Adjustment for age, BMI at blood draw, smoking status, primiparity and gestational age at blood draw did not change these results. In addition, the results were similar studying the preeclamptic and superimposed preeclamptic groups separately.
The power of our study to detect the observed differences in serum Hsp70 concentration between the control group and patients with transient hypertension of pregnancy, preeclampsia and superimposed preeclampsia, at a Type I error rate of 0.05, was greater than 99.9% in each comparison.
Discussion
We measured serum Hsp70 concentration in 142 pregnant women with hypertensive disorders (93 with preeclampsia, 29 with transient hypertension and 20 with superimposed preeclampsia) and in 127 normotensive, healthy pregnant women. The serum Hsp70 concentration was significantly higher in patients with transient hypertension of pregnancy, in preeclamptic patients and in patients with superimposed preeclampsia than in the control group. The observed association seems to be independent from potential confounding variables, 28 reported increased concentration of Hsp72 in placental tissues in response to ischaemiareperfusion, a model for oxidative stress in preeclampsia. In a recently published study from Hnat et al., 29 there was no significant difference in immunostaining intensity for Hsp70 in placentas from preeclamptic pregnancies compared to those from normotensive pregnancies. However, placental bed biopsies were not obtained in this study.
In a pilot study, Jirecek et al. 23 observed higher serum levels of Hsp70 in patients with early onset of severe preeclampsia. Fukushima et al. 24 reported significantly higher Hsp70 serum levels in preeclampsia. However, in the latter study, preterm delivery high-risk patients were primarily investigated and there were only seven patients with preeclampsia.
Conversely, Livingston et al. 25 did not find higher plasma levels of Hsp70 in women with severe preeclampsia. However, according to their results, the scatter of plasma Hsp70 levels in preeclamptic patients was much higher than in normotensive pregnant women. Their control group included patients with premature rupture of membranes, patients with premature labour as well as patients with placental abruptions. In addition, ethnical differences between participants of their and our studies may also account for dissimilar results.
Our study extends the above-mentioned three studies with relevant new information about circulating Hsp70 concentrations in hypertensive disorders of pregnancy. The power of our study was greater than 99.9% in each comparison, and our control group consisted of well-selected, healthy pregnant women without any pathological condition. In addition, pregnant women with transient hypertension and superimposed preeclampsia were also included in our study.
In the groups of preeclamptic and superimposed preeclamptic patients, we did not find statistically significant differences in serum Hsp70 concentration between mild and severe preeclamptic patients, between patients with late and early onset of the disease as well as between preeclamptic patients without and with foetal growth restriction. Furthermore, we did not find a significant difference in serum Hsp70 concentration among patients with transient hypertension, preeclampsia and superimposed preeclampsia. We hypothesize that in these conditions, haemodynamic stress, oxidative stress (placental or systemic), placental ischaemia, ischaemia of other organs as well as maternal systemic inflammatory response increase the expression of Hsp70, resulting in elevated circulating Hsp70 levels. Indeed, haemodynamic stress (acute hypertension) can induce Hsp expression in the vessel wall. 12, 22 Inflammatory cytokines, ischaemia and free oxygen radicals are also able to induce Hsp70 expression. 1 However, the source of circulating Hsps in healthy individuals, as well as in patients with pathological conditions has not been identified yet. It is also not known whether circulating Hsp70 concentration reflects intracellular concentration. In pregnancy, the role of the placenta also needs to be considered in this issue. In addition, not only can Hsps be released from viable cells, but they might also be discharged from necrotized and apoptotic cells. 1 Circulating Hsp70 may not only be a marker for transient hypertension of pregnancy, preeclampsia and superimposed preeclampsia, but might also play a role in their pathogenesis. Hsps are usually considered to be intracellular proteins with molecular chaperone and cytoprotective functions. 30 Circulating Hsps may also be cytoprotective, as exogenous Hsp70 increases the survival of stressed arterial smooth muscle cells in culture via cell surface binding, 31, 32 and protects cells from apoptosis. 33 They could act as intercellular stress signalling molecules and may represent an ancestral danger signal of a non-physiological condition to elicit innate and adaptive proinflammatory immune responses. 34 Extracellular Hsp70 has been reported to bind to specific receptors (CD14, CD91 and Toll-like receptors) on antigen-presenting cells and to stimulate proinflammatory cytokine (tumour necrosis factor-a, interleukin (IL)-1b and IL-6) production. [35] [36] [37] Extracellular Hsp70 has been suggested to have a dual role as chaperone and cytokine. In addition, our research group has previously found that Hsp70 is a potent activator of the classical pathway of the complement system. 38 We found that a pregnant woman with high serum Hsp70 level (X0.41 ng/ml) has an increased risk of preeclampsia, transient hypertension and superimposed preeclampsia. However, a limitation of our study is that it was designed as a case-control study. A prospective study should be carried out to determine whether elevated serum Hsp70 level precedes the development of preeclampsia, transient hypertension and superimposed preeclampsia, and thus can help to predict these conditions. Furthermore, the changes in serum Hsp70 concentration during the course of pregnancy are not known. Therefore, serum Hsp70 levels need to be determined throughout gestation in normal pregnancies, as well as in pregnancies complicated with hypertensive disorders.
In summary, according to our results, serum Hsp70 concentration is elevated in patients with transient hypertension of pregnancy, in preeclamptic patients as well as in patients with superimposed preeclampsia compared with normotensive, healthy pregnant women. Circulating Hsp70 may not only be a marker for these conditions, but might also play a role in their pathogenesis. However, further studies are needed to explore the role of circulating Hsp70 in the pathogenesis of hypertensive disorders of pregnancy.
